Faculty

32 1a 2a

61 16

Matthew John Atherton, BVSc, MVM, PhD

7 4 1 23

1f Graduate Group Affiliations 8

Immunology
Cell and Molecular Biology

46 Contact information
2d

Email:
mattath@upenn.edu

4 3 3 1d

18 Publications
23

d8 6f

26 Search PubMed for articles c

3 2 4 b 1f

13 Education:
21 a BVSc 20 (Veterinary Medicine) c
2e University of Bristol, 2005.
21 8 PhD 32 (Medical Sciences-Infection & Immunity) c
2d McMaster University , 2017.
c

3 27

Links
124 Search PubMed for articles
d

5 3 3 92 Permanent link
2 29

b6 > Perelman School of Medicine > Faculty > Details a

1e 1d

Description of Clinical Expertise

20 Medical oncology
71

Description of Research Expertise

15f Defining the prognostic and therapeutic role of T cells in hematologic neoplasms utilizing a multi-species comparative approach. Identification and appraisal of novel targets for T cell-based immunotherapy in clinical trials of canine patients with spontaneous and aggressive tumors bearing translational importance for human oncology.
e 29

Selected Publications

233 Zhang, H., Yu, P., Tomar, V. S., Chen, X., Atherton, M. J., Lu, Z., Zhang, H. G., Li, S., Ortiz, A., Gui, J., Leu, N. A., Yan, F., Blanco, A., Meyer-Ficca, M. L., Meyer, R. G., Beiting, D. P., Li, J., Nunez-Cruz, S., O'Connor, R. S., Johnson, L. R., Minn, A. J., George, S. S., Koumenis, C., Diehl, J. A., Milone, M. C., Zheng, H., Fuchs, S. Y.: Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nat Cancer 3(7): 808-820, 2022.

c5 Atherton, M. J., Mason, N. J.: Bite-size introduction to canine hematologic malignancies. Blood Adv 6(13): 4073-4084, 2022.

139 Atherton, M. J., Rotolo, A., Haran, K. P., Mason, N. J.: Case report: clinical and serological hallmarks of cytokine release syndrome in a canine B cell lymphoma patient treated with autologous CAR-T cells. Front Vet Sci 9: 824982, 2022.

1a1 Gedney, A., Salah, P., Mahoney, J. A., Krick, E., Martins, R., Scavello, H., Lenz, J. A., Atherton, M. J.: Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I''m-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma. Veterinary and Comparative Oncology 20(3): 688-696, 2022.

19d Lenz, J. A., Assenmacher, C. A., Costa, V., Louka, K., Rau, S., Keuler, N. S., Zhang, P. J., Maki, R. G., Durham, A. C., Radaelli, E., Atherton, M. J.: Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma. Cancer Immunology, Immunotherapy 2021.

120 Rotolo, A., Atherton, M. J., Kasper, B. T., Haran, K. P., Mason, N. J.: Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer. STAR Protoc 2(4): 100905, 2021.

254 LeBlanc, A. K., Atherton, M., Bentley, R. T., Boudreau, C. E., Burton, J. H., Curran, K. M., Dow, S., Giuffrida, M. A., Kellihan, H. B., Mason, N. J., Oblak, M., Selmic, L. E., Selting, K. A., Singh, A., Tjostheim, S., Vail, D. M., Weishaar, K. M., Berger, E. P., Rossmeisl, J. H., Mazcko, C.: Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Veterinary and Comparative Oncology 19(2): 311-352, 2021.

16d Benjamin, S. E., Sorenmo, K. U., Krick, E. L., Salah, P., Walsh, K. A., Weinstein, N. M., Keuler, N. S., Avery, A. C., Atherton, M. J., Lenz, J. A.: Response-based modification of CHOP chemotherapy for canine B-cell lymphoma. Veterinary and Comparative Oncology 19(3): 541-550, 2021.

179 Pol, J. G., Atherton, M. J., Stephenson, K. B., Bridle, B. W., Workenhe, S. T., Kazdhan, N., McGray, A. R., Wan, Y., Kroemer, G., Lichty, B. D.: Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. J Immunother Cancer 8(2), 2020.

174 Panjwani, M. K., Atherton, M. J., MaloneyHuss, M. A., Haran, K. P., Xiong, A., Gupta, M., Kulikovsaya, I., Lacey, S. F., Mason, N. J.: Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. Oncoimmunology 9(1): 1676615, 2020.

105 Atherton, M. J., Lenz, J. A., Mason, N. J.: Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy? Veterinary and Comparative Oncology 18(4): 447-470, 2020.

278 Pol, J. G., Acuna, S. A., Yadollahi, B., Tang, N., Stephenson, K. B., Atherton, M. J., Hanwell, D., El-Warrak, A., Goldstein, A., Moloo, B., Turner, P. V., Lopez, R., LaFrance, S., Evelegh, C., Denisova, G., Parsons, R., Millar, J., Stoll, G., Martin, C. G., Pomoransky, J., Breitbach, C. J., Bramson, J. L., Bell, J. C., Wan, Y., Stojdl, D. F., Lichty, B. D., McCart, J. A.: Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology 8(1): e1512329, 2019.

18b Pol, J. G., Atherton, M. J., Bridle, B. W., Stephenson, K. B., Le Boeuf, F., Hummel, J. L., Martin, C. G., Pomoransky, J., Breitbach, C. J., Diallo, J. S., Stojdl, D. F., Bell, J. C., Wan, Y., Lichty, B. D.: Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virother 7: 117-128, 2018.

1e2 Atherton, M. J., Stephenson, K. B., Tzelepis, F., Bakhshinyan, D., Nikota, J. K., Son, H. H., Jirovec, A., Lefebvre, C., Dvorkin-Gheva, A., Ashkar, A. A., Wan, Y., Stojdl, D. F., Belanger, E. C., Breau, R. H., Bell, J. C., Saad, F., Singh, S. K., Diallo, J. S., Lichty, B. D.: Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncoimmunology 7(7): e1445459, 2018.

13c Atherton, M. J., Stephenson, K. B., Nikota, J. K., Hu, Q. N., Nguyen, A., Wan, Y., Lichty, B. D.: Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine 36(16): 2181-2192, 2018.

2c

7 1d

2c back to top
26 Last updated: 09/28/2023
34 The Trustees of the University of Pennsylvania c

1 49 2 2 1a 32 34